BMO Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained its Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and raised the price target from $170 to $200.
June 24, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has maintained its Outperform rating on Sarepta Therapeutics and raised the price target from $170 to $200, indicating strong confidence in the company's future performance.
The raised price target and maintained Outperform rating from a reputable analyst firm like BMO Capital suggests positive sentiment and expected growth for Sarepta Therapeutics. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100